FDA advisory panel endorses GRAIL's Galleri as multi-cancer early detection blood test
An FDA advisory panel has voted that there is reasonable evidence supporting the effectiveness of GRAIL’s (GRAL) multi-cancer early detection blood test, known as Galleri. The Molecular and Clinical Genetics Panel of the Medical Devices Advisory Committee approved it with a vote of 6-4. This endorsement could pave the way for regulatory clearance or approval from the FDA in the near future. GRAIL's Galleri is designed to detect multiple types of cancer at an early stage using a single blood test, potentially offering significant benefits in terms of early diagnosis and treatment outcomes. The decision reflects growing interest in liquid biopsy technologies as part of broader efforts to improve cancer screening methods.
Tickers: $GRAL
Topics: blood test cancer detection FDA medical devices